For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07227402?term=MK-6482-033&viewType=Card&rank=1
MK-6482-033: A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Genitourinary
Study Status:
Open to Accrual
Principal investigator:
Paul Celano, MD
IRB number :
2429990
Study Number:
G2511
Phone:
Fax:
MK1084-012: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gastrointestinal
Study Status:
Open to Accrual
Principal investigator:
Gang Chen, MD, PhD
IRB number :
2362784
Study Number:
G2503
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06997497?term=kandlelit-012&viewType=Card&limit=10&sort=@relevance&rank=1
MK1084-014: A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab in Participants with KRAS G12C Mutant, Advanced Solid Tumors (KANDLELIT-014)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Selected Cancers
Study Status:
Open to Accrual
Principal investigator:
Paul Celano, MD
IRB number :
2381957
Study Number:
G2507
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07209111?term=MK-1084-014&rank=1
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Robert Donegan, MD
IRB number :
2151828
Study Number:
NRG-BR009
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05879926
NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation with BMX-001 in Patients with Head and Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Head and Neck
Study Status:
Open to Accrual
Principal investigator:
Kruti Patel, MD
IRB number :
2343602
Study Number:
NRG-CC013
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06532279?term=cc013&limit=10&sort=@relevance&rank=1